Syndax Pharmaceuticals (SNDX) News Today → A new way to collect income from stocks (From DTI) (Ad) Free SNDX Stock Alerts $20.87 -0.10 (-0.48%) (As of 10:06 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Moderate Buy" from Analystsamericanbankingnews.com - April 22 at 2:30 AMFinancial Analysis: Syndax Pharmaceuticals (NASDAQ:SNDX) and Biofrontera (NASDAQ:BFRI)americanbankingnews.com - April 18 at 4:10 AMSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forumfinance.yahoo.com - April 10 at 7:46 PMSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forumprnewswire.com - April 10 at 4:05 PMAnalysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Legend Biotech (LEGN)markets.businessinsider.com - April 8 at 11:51 PMBuy Rating Affirmed for Syndax Pharmaceuticals Amidst Strong Clinical Results and Strategic Growth Prospectsmarkets.businessinsider.com - April 8 at 6:50 PMSyndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Sessionprnewswire.com - April 8 at 7:00 AMSyndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)finanznachrichten.de - April 6 at 8:34 AMCrinetics Pharmaceuticals gains amid pitch at Sohn charity conference (update)msn.com - April 3 at 1:44 PM20 European Cities with Highest Weed Consumptionmsn.com - March 29 at 7:06 AMThis longevity company is letting you check the ‘credit score’ for your health. Here are my surprising results and biological agemsn.com - March 29 at 2:06 AMSyndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDAmsn.com - March 28 at 11:04 AMSyndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemiafinance.yahoo.com - March 28 at 11:04 AMSyndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hopeseekingalpha.com - March 28 at 7:54 AMAnalysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Quanterix (QTRX)markets.businessinsider.com - March 27 at 1:32 PMSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 4.9%marketbeat.com - March 27 at 12:44 PMTraders Purchase Large Volume of Syndax Pharmaceuticals Put Options (NASDAQ:SNDX)marketbeat.com - March 27 at 11:45 AMSyndax Says Revumenib NDA Granted FDA Priority Reviewmarketwatch.com - March 27 at 8:32 AMSyndax Announces FDA Priority Review Of NDA For Revumenib For Treatment Of R/R KMT2Ar Acute Leukemiamarkets.businessinsider.com - March 27 at 8:32 AMFDA grants priority review for Syndax leukemia drug, sets action datemsn.com - March 27 at 8:32 AMSyndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemiafinance.yahoo.com - March 27 at 8:32 AMSyndax Pharmaceuticals' (SNDX) Buy Rating Reiterated at HC Wainwrightmarketbeat.com - March 27 at 8:18 AMSyndax Pharmaceuticals: Syndax Announces Appointment of Steven Closter as Chief Commercial Officerfinanznachrichten.de - March 18 at 10:26 AMSyndax Announces Appointment of Steven Closter as Chief Commercial Officerfinance.yahoo.com - March 18 at 10:26 AMWellington Management Group LLP Has $110.97 Million Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)marketbeat.com - March 17 at 4:54 AMSNDX Apr 2024 17.500 putfinance.yahoo.com - March 16 at 6:45 PMSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.1% marketbeat.com - March 13 at 2:57 PMHudson Bay Capital Management LP Acquires 761,186 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)marketbeat.com - March 13 at 10:42 AMHere's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situationfinance.yahoo.com - March 13 at 10:08 AMAdage Capital Partners GP L.L.C. Boosts Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)marketbeat.com - March 9 at 6:35 AMBuy Rating for Syndax Pharmaceuticals Amidst Strategic Progress and Regulatory Milestonesmarkets.businessinsider.com - March 6 at 5:33 PMSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 3 at 11:54 AMSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)prnewswire.com - March 1 at 4:05 PMSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Palo Alto Investors LPmarketbeat.com - March 1 at 10:27 AMSyndax Pharmaceuticals, Inc. Forecasted to Earn Q2 2024 Earnings of ($1.04) Per Share (NASDAQ:SNDX)marketbeat.com - March 1 at 8:00 AMSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to Post Q1 2024 Earnings of ($1.00) Per Share, B. Riley Forecastsmarketbeat.com - February 29 at 7:54 AMBuy Rating Affirmed for Syndax Pharmaceuticals Amid Strong Clinical Results and Solid Financial Outlookmarkets.businessinsider.com - February 28 at 4:36 PMScotiabank Keeps Their Hold Rating on Syndax Pharmaceuticals (SNDX)markets.businessinsider.com - February 28 at 4:36 PMSyndax Pharmaceuticals (NASDAQ:SNDX) Issues Earnings Resultsmarketbeat.com - February 28 at 10:42 AMSyndax Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentationseekingalpha.com - February 27 at 9:21 PMSyndax Pharmaceuticals: Q4 Earnings Insightsbenzinga.com - February 27 at 8:04 PMSyndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Updatefinance.yahoo.com - February 27 at 8:04 PMSyndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Updateprnewswire.com - February 27 at 4:05 PMSyndax Pharmaceuticals Q4 2023 Earnings Previewmsn.com - February 26 at 7:12 PMEarnings Preview: Syndax Pharmaceuticalsbenzinga.com - February 26 at 2:12 PMSyndax Announces Participation at Two Upcoming Investor Conferencesprnewswire.com - February 26 at 7:00 AMSyndax Pharmaceuticals Inc (SNDX)investing.com - February 24 at 1:55 PMSyndax Pharmaceuticals (SNDX) to Release Earnings on Tuesdaymarketbeat.com - February 21 at 8:58 AMSyndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024finance.yahoo.com - February 20 at 6:24 PMSyndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024prnewswire.com - February 20 at 4:05 PM Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address The system that called 2023’s top 7 stocks is at it again… (Ad)Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today. Just follow this link here! SNDX Media Mentions By Week SNDX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNDX News Sentiment▼-0.050.44▲Average Medical News Sentiment SNDX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNDX Articles This Week▼23▲SNDX Articles Average Week Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SDGR News CPRX News GPCR News NAMS News RNA News HRMY News PTCT News AMRX News GLPG News GERN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNDX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingNew Trump BombshellThe Freeport SocietyThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
